Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40629-021-00178-2 http://scihub22266oqcxt.onion/10.1007/s40629-021-00178-2 34178577!8212077!34178577     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34178577&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Allergo+J+Int 2021 ; 30 (5): 155-168 Nephropedia Template TP {{tp|p=34178577|t=2021. Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper |pdf=|usr=}}{{34178577}} gab.com Text Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper JO: Allergo J Int http://www.kidney.de/pget.php?&tw=1&pmid=34178577 #FOAvip BACKGROUND: The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. RESULTS: This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered. CONCLUSION: Despite the need for a patient-specific risk-benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects. Twit Text FOAVip Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper ????Allergo J Int http://www.kidney.de/pget.php?&tw=1&pmid=34178577 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34178577 #FOAvip English Wikipedia <ref>{{Cite pmid|34178577}}</ref> Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper #MMPMID34178577 Untersmayr E; Forster-Waldl E; Bonelli M; Boztug K; Brunner PM; Eiwegger T; Eller K; Goschl L; Grabmeier-Pfistershammer K; Hotzenecker W; Jordakieva G; Moschen AR; Pfaller B; Pickl W; Reinisch W; Wiedermann U; Klimek L; Bergmann KC; Brehler R; Pfutzner W; Novak N; Merk H; Rabe U; Schlenter W; Ring J; Wehrmann W; Mulleneisen N; Wrede H; Fuchs T; Jensen-Jarolim E Allergo J Int 2021[]; 30 (5): 155-168 PMID34178577show ga BACKGROUND: The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. RESULTS: This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered. CONCLUSION: Despite the need for a patient-specific risk-benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects. ?Immunologically relevant aspects of the new COVID-19 vaccines-an OGAI (epmc).pdf DeepDyve Pubget Overpricing